Pdt Partners, LLC Eiger Bio Pharmaceuticals, Inc. Transaction History

Pdt Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$7.98 - $12.29 $144,773 - $222,965	-18,142 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$7.96 - $12.42 $144,410 - $225,323	18,142 New	18,142 $148,000
Q1 2019 May 15, 2019	SELL	$10.31 - $14.38 $131,968 - $184,064	-12,800 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$8.63 - $12.4 $18,986 - $27,280	2,200 Added 20.75%	12,800 $130,000
Q3 2018 Nov 14, 2018	SELL	$9.6 - $12.9 $243,984 - $327,853	-25,415 Reduced 70.57%	10,600 $127,000

Q2 2018 Aug 14, 2018	BUY	$8.3 - $16.8 $112,174 - $227,052	13,515 Added 60.07%	36,015 $439,000
Q1 2018 May 15, 2018	BUY	$8.1 - $16.0 $182,250 - $360,000	22,500 New	22,500 $222,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $496M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.